Q2 EPS Estimate for Anavex Life Sciences Boosted by Analyst

Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) - Stock analysts at HC Wainwright upped their Q2 2025 earnings estimates for shares of Anavex Life Sciences in a research report issued on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.16) per share for the quarter, up from their previous forecast of ($0.18). HC Wainwright currently has a "Buy" rating and a $42.00 target price on the stock. The consensus estimate for Anavex Life Sciences' current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Anavex Life Sciences' Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.69) EPS.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03.

Separately, D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research note on Wednesday, February 12th.

Anavex Life Sciences Trading Down 0.8 %

Anavex Life Sciences stock traded down $0.07 during trading on Thursday, reaching $8.28. The company had a trading volume of 728,840 shares, compared to its average volume of 1,475,266. The firm has a market capitalization of $704.33 million, a price-to-earnings ratio of -15.05 and a beta of 0.69. The firm's 50-day simple moving average is $9.97 and its 200 day simple moving average is $7.80. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $14.44.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AVXL. Vermillion Wealth Management Inc. bought a new stake in Anavex Life Sciences during the fourth quarter valued at about $34,000. Tower Research Capital LLC TRC raised its stake in Anavex Life Sciences by 102.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 1,708 shares during the period. Orion Capital Management LLC lifted its holdings in Anavex Life Sciences by 666.7% in the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 10,000 shares in the last quarter. PVG Asset Management Corp purchased a new position in Anavex Life Sciences in the 3rd quarter worth approximately $74,000. Finally, Atria Investments Inc bought a new position in Anavex Life Sciences in the 3rd quarter worth approximately $76,000. Hedge funds and other institutional investors own 31.55% of the company's stock.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.